CTOs on the Move

Neovasc

www.neovasc.com

 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.neovasc.com
  • 13562 Maycrest Way #5138
    Richmond, BC CAN V6V 2J7
  • Phone: 604.270.4344

Executives

Name Title Contact Details

Funding

Neovasc raised $12M on 05/14/2019
Neovasc raised $10M on 01/11/2020
Neovasc raised $72M on 02/10/2021

Similar Companies

Medstrat

Medstrat is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Safecross First Aid

Safecross First Aid Ltd. is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Molnlycke

A world-leading medical solutions company We design and supply medical solutions to enhance performance in healthcare – from the hospital to the home.

Medical Supply Corporation

Medical Supply Corporation is a Ferndale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LumiThera

At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.